Sponsor study identifier
interventional
28
1 country
3
Study Start
June 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
April 2007
Date type not reportedThis date has not been verified as actual or estimated.
The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2007
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2005
Date type not reportedThis date has not been verified as actual or estimated.
December 30, 2005
Actual (reported)January 4, 2006
Actual (reported)April 2007
Date type not reportedThis date has not been verified as actual or estimated.
The primary objective is to establish the maximally tolerated dose of bortezomib that can be administered with thalidomide in patient with myelodysplasia.
Assess efficacy in terms of the number of patients attaining a 50% reduction in blast percentage, or 50% reduction in number of red blood cell and/or platelet transfusions.
Determine the toxicity profile of bortezomib when used in combination with thalidomide for patients with myelodysplasia.
Determine the relationship between NF-kB expression and clinical response to bortezomib and thalidomide.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Karen Ballen, M
Massachusetts General Hospital, Harvard University
First Submitted
December 30, 2005
First Posted
January 4, 2006
Study Start
June 2005
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
April 2007
Date type not reportedA Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
March 13, 2008
Record last verified: 2008-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: